Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254355 | 0.86 | ROCK2 (1.00) | ROCK2CYP3A4ROCK1DHFRNPC1 | |
| SCHEMBL10036351 | 0.86 | ROCK2 (0.79) | ROCK2CYP3A4ROCK1DHFRPOLA1 | |
| SCHEMBL10036350 | 0.86 | ROCK2 (0.79) | ROCK2CYP3A4ROCK1DHFRPOLA1 | |
| SCHEMBL5254631 | 0.86 | ROCK2 (0.70) | ROCK2CYP3A4ROCK1AURKBPDPK1 | |
| SCHEMBL6396934 | 0.84 | ROCK2 (1.00) | ROCK2CYP3A4ROCK1AURKB | |
| SCHEMBL716799 | 0.84 | ROCK2 (0.76) | ROCK2CYP3A4ROCK1AURKBPDPK1 | |
| SCHEMBL6387624 | 0.83 | ROCK2 (0.74) | ROCK2CYP3A4ROCK1DHFRPOLA1 | |
| SCHEMBL10036325 | 0.83 | ROCK2 (0.74) | ROCK2CYP3A4ROCK1AURKBDHFR | |
| SCHEMBL723650 | 0.83 | ROCK2 (0.68) | ROCK2CYP3A4ROCK1AURKBDHFR | |
| SCHEMBL10036321 | 0.81 | ROCK2 (0.71) | ROCK2CYP3A4ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20050209261-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-22 | — | — | US | disclosed |
| US-6943172-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040002507-A1 | Rho-kinase inhibitors | BAYER CORPORATION (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002507-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP3A4 2878/4885ROCK1 2/4885 |
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP3A4 2878/4885ROCK1 2/4885 |
| US-20050209261-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP3A4 2878/4885ROCK1 2/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP3A4 2878/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.